The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study

Last updated: March 12, 2025
Sponsor: PeriPharm
Overall Status: Completed

Phase

N/A

Condition

Cancer

Lymphoproliferative Disorders

Leukemia

Treatment

No intervention

Clinical Study ID

NCT06610045
PROxy202301
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL. Additionally, this study will assess the correlation between QoL, obtained from commonly used and validated questionnaires, and the perceptions of both patients and caregivers respectively., obtain from a 10-point scale and a comment box.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. 18 years of age or older;

  2. Part of the Myeloma Canada database;

  3. Identified as a patient with MM or

  4. Identified as a current caregiver of a patient with MM at the time ofparticipation.

  5. Ability to read and understand English or French;

  6. Signature of informed consent form (ICF).

Exclusion

Exclusion Criteria:

No exclusion criteria

Study Design

Total Participants: 400
Treatment Group(s): 1
Primary Treatment: No intervention
Phase:
Study Start date:
October 15, 2024
Estimated Completion Date:
March 12, 2025

Study Description

Potential participants will be identified by Myeloma Canada using their database. Myeloma Canada is a registered non-profit organization created by, and for, Canadians impacted by multiple myeloma. As part of Myeloma Canada website, patients and caregivers can subscribe to a mailing list to receive their monthly newsletter and to participate in surveys. This database comprises about 5,000 individuals, including patients and caregivers.

An e-mail will be sent to 600 patients and 200 caregivers randomly selected to invited them to participate in the survey. Interested participants will be invited to visit the Participant Portal on the PROxy website (https://periproxy.com/en), to sign the informed consent form and complete online questionnaires. Upon request, paper-based documents (i.e., informed consent form and questionnaires) can also be sent by mail. The following questionnaires will be used:

Patients

  • Patient Information Questionnaire (i.e., baseline characteristics)

  • EORTC QLQ-C30

  • EORTC QLQ-MY20

  • EQ-5D-5L

  • ESAS-R

  • Patients Perspective

Caregivers

  • Caregiver Information Questionnaire (i.e., baseline characteristics)

  • CarGOQoL

  • Caregivers Perspective

If the sample size (i.e., 300 patients and 100 caregivers) is not reached one month after the first e-mail, an invitation e-mail will be sent to an additional 600 eligible patients and/or 200 caregivers randomly selected. This scheme of participant identification will be performed until the sample size is reached.

Connect with a study center

  • PROxy Network, an initiative of PeriPharm inc.

    Montreal, Quebec H2Y 2H4
    Canada

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.